Investors

Boston, February 4, 2022—GreenLight Biosciences, PBC, a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, today announced its agreement to operate a field research station in Spain.  

Located south of Seville, a key agricultural area with intensive year-round production, the farmland will allow GreenLight to accelerate its transition of research and discovery compounds into the field.

“The versatility of this site and its climate will enable us to conduct broad-spectrum testing for GreenLight’s emerging portfolio and support key projects, whether it’s plant diseases or insects,” says Andreas Hopf, VP of Plant Health Product Development. 

GreenLight intends to lease about 10 to 20 hectares to support field trials, plant pathogens, entomology, and office space. “Having a research farm allows us to conduct our field work much more efficiently,” says Hopf. “We will have the core competencies to take on external compounds and technologies to onboard them onto our pipeline.”

The expansion will initially support GreenLight’s work in Europe to address crop challenges caused by powdery mildew, botrytis, fusarium, and the Colorado potato beetle.

About GreenLight

Founded in 2008, GreenLight aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA  to protect honeybees and a range of crops. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective production of RNA. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. GreenLight is a public benefit corporation that trades under the ticker GRNA on Nasdaq. For more information, visit https://www.greenlightbiosciences.com/

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and GreenLight assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Thomas Crampton

SVP & Head of Corporate Affairs

GreenLight Biosciences

[email protected]

+44 7826 995794

+1-914-202-2762

BOSTON, February 3, 2022—GreenLight Biosciences (“GreenLight”), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp. (Nasdaq: ENVI) (“ENVI”), a special purpose acquisition company, yesterday announced the closing of their previously announced business combination. 

In connection with the closing, the company changed its name to GreenLight Biosciences Holdings, public-benefit corporation, with shares of Class A common stock and public warrants trading today on Nasdaq under the ticker symbols “GRNA” and “GRNA.WS” respectively. The business combination was approved at a special meeting of ENVI stockholders on February 1, 2022.

GreenLight harnesses the power of biology to develop RNA-based solutions for some of humanity’s greatest challenges in human health through mRNA vaccines and therapeutics and in food production through RNA crop-protection products. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective and scalable production of RNA.

“Today an exciting new chapter begins as we become a publicly listed company and public-benefit corporation,” said CEO Andrey Zarur. “We are thrilled to accelerate commercialization by attracting the talent, investing in the tools, and scaling our manufacturing infrastructure to continue developing our platform for design, development, and production of unprecedented new applications for RNA.”

“In creating ENVI, our goal was to partner and combine with a high-growth, technology-rich business, propelled by a large market opportunity and a business model supporting critical sustainability initiatives,” said Dan Coyne, CEO of Environmental Impact Acquisition Corp. “GreenLight has an impressive pipeline of RNA products spanning human, animal, and plant health, and its exceptional team understands what it takes to deliver breakthrough technology to market. We are extremely pleased to have completed this transaction, resulting in GreenLight becoming a public company.”

SVB Leerink and Credit Suisse served as financial and capital markets advisors to GreenLight and co-placement agents on the PIPE transaction. Foley Hoag LLP served as legal advisor to GreenLight. Canaccord Genuity served as financial advisor and Latham & Watkins LLP served as legal advisor to Environmental Impact Acquisition Corp. 

To celebrate the completion of the business combination, GreenLight will ring the closing bell at Nasdaq at 4 p.m. ET on February 8, 2022. 

About GreenLight Biosciences

GreenLight Biosciences aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. Our RNA platform allows us to research, design, and manufacture for human, animal, and plant health. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA  to protect honeybees and a range of crops. The company’s platform is protected by numerous patents. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. GreenLight is a public benefit corporation that trades under the ticker GRNA on Nasdaq.  For more information, visit GreenLight’s website.

About Environmental Impact Acquisition Corporation

Environmental Impact Acquisition Corp. is a Special Purpose Acquisition Company. The Company is sponsored by CG Investments Inc. VI, an affiliate of Canaccord Genuity, which manages several investment vehicles.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquisition Corp. (“ENVI”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities and the effect of the announcement or pendency of the transaction on GreenLight’s business relationships, operating results, and business generally. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Media contact:

Thomas Crampton

SVP & Head of Corporate Affairs

GreenLight Biosciences

[email protected]

+44 7826 995794

+1-914-202-2762

Investor contact:

[email protected]

Boston, February 2, 2022—Environmental Impact Acquisition Corporation (NASDAQ: ENVI), a publicly-traded special purpose acquisition company, announced today that its business combination with Greenlight Biosciences was approved in a shareholder vote held yesterday, with 80.7% of shareholders participating in the vote and 78.6% voting in favor of the combination.

Subject to the satisfaction or waiver of the other customary closing conditions, Environmental Impact Acquisition Corp. anticipates closing the business combination today. In connection with the closing, the company will change its name to GreenLight Biosciences Holdings, public-benefit corporation, and the combined company’s shares of Class A common stock and public warrants are expected to trade on the Nasdaq exchange beginning on February 3, 2022, under the ticker symbols “GRNA” and “GRNA.WS,” respectively.

“Today marks an important milestone, and I am thrilled to work with our teams as we develop new applications for our RNA platform,” said Andrey Zarur, CEO of GreenLight.

Investors include Serum Life Sciences, Fall Line Capital, Viceroy Capital, S2G Ventures, Cormorant Asset Management, Morningside Venture Investments, Hudson Bay Capital, BNP Paribas Ecosystem Restoration Fund, The Jeremy and Hannelore Grantham Environmental Trust, Continental Grain Company, Pura Vida Investments LLC, Xeraya Capital, and MLS Fund II/Spruce.

Canaccord Genuity served as financial advisor and Latham & Watkins LLP served as legal advisor to Environmental Impact Acquisition Corp.  SVB Leerink and Credit Suisse served as financial and capital markets advisors to GreenLight and co-placement agents on the PIPE transaction. Foley Hoag LLP is served as legal advisor to GreenLight.

About GreenLight

Founded in 2008, GreenLight aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA  to protect honeybees and a range of crops. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective production of RNA. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. For more information, visit https://www.greenlightbiosciences.com/

In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI).

For more information, visit greenlightbiosciences.com

About Environmental Impact Acquisition Corporation

Environmental Impact Acquisition Corp. is a Special Purpose Acquisition Company. The Company is sponsored by CG Investments Inc. VI, an affiliate of Canaccord Genuity, which manages several investment vehicles.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquisition Corp. (“ENVI”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities and the effect of the announcement or pendency of the transaction on GreenLight’s business relationships, operating results, and business generally. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Thomas Crampton

SVP & Head of Corporate Affairs

GreenLight Biosciences

[email protected]

+44 7826 995794

+1-914-202-2762

BOSTON, January 31, 2022 – GreenLight Biosciences and Germains Seed Technology, an industry leader in seed treatment technologies, today announced a research partnership agreement that could lead to the first commercial use of RNA as a seed treatment to control crop diseases and offer options to farmers looking for innovative solutions.

Through the partnership, the two companies will explore synergies between Germains’ seed priming and coating technologies and GreenLight’s dsRNA expertise and ability to cost-effectively scale manufacturing to protect vegetable crops. In October 2021, GreenLight announced that the company had achieved, for the first time ever, effective field control of fungal pathogens using double-stranded RNA. 

“Farmers and agribusinesses are looking for effective, affordable and sustainable alternatives to traditional crop protection, particularly as environmental and market pressures to do so continue to increase,” said Mark Singleton, GreenLight’s Senior Vice President of Technology & External Innovation.

“We’re excited to work with the leading seed treatment experts at Germains to develop potential additional applications for RNA to address those challenges,” he said. “Our ability to produce large-scale commercial quantities of RNA at low cost and with high quality in our Rochester, New York, facility means we are well-positioned to quickly commercialize and scale new products in our pipeline.”

“Germains Seed Technology has been a leader in the international seed industry for 150 years, and our strength as a company is rooted in our commitment to innovation as we seek to maximize nature’s potential and meet customers’ needs,” said Dale Krolikowski, Germains’ Head of Business Development and Research.

“We believe this new partnership with GreenLight Biosciences has the potential to build a new generation of products that do just that. RNA technology presents enormous potential for the seed treatment industry, and we are thrilled to be working with the innovators at GreenLight to push the industry forward.” 

GreenLight’s technology complements Germains’ Health brand, which has delivered several novel seed treatments over the last few years, including Ultim^®-ST organic protection against Pythium. The partnership will allow Germains to provide further innovation to customers as the company works to address seed-borne and soil-borne pathogens, which continue to cause dramatic crop losses every year.

The fast-growing seed treatment market is valued at approximately $6.5 billion, with an estimated growth rate between 10 and 12 percent annually. If successful, this partnership would mark a key addition to GreenLight’s portfolio and intended pipeline of agricultural products, as well as a critical addition to Germains’ offerings of innovative seed treatments and grower solutions. 

In 2022, GreenLight anticipates receiving U.S. regulatory approval of its RNA-based product for controlling the Colorado potato beetle and intends to submit its honeybee health solution to the U.S. Environmental Protection Agency. The company has seven agricultural products in development with an addressable market of $6 billion that it plans to launch by 2026.

About GreenLight

Founded in 2008, GreenLight aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective production of RNA. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. For more information, visit https://www.greenlightbiosciences.com/

In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI).

About Germains Seed Technology

Celebrating 150 years of serving the agriculture industry, Germains has sales offices and research facilities in North America, the United Kingdom, and Europe. Germains Seed Technology is committed to delivering industry-leading innovative seed technologies for sugar beet, vegetable, and field crops for seed producers, dealers, and growers globally. For more information, go to http://germains.com. 

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquisition Corp. (“ENVI”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities and the effect of the announcement or pendency of the transaction on GreenLight’s business relationships, operating results, and business generally. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:

Thomas Crampton

SVP & Head of Corporate Affairs, GreenLight Biosciences

[email protected]

+44 7826 995794 +1-914-202-2762

ENVI Announces Quorum to Pass Business Combination With GreenLight Biosciences and Achievement of All Transaction Requirements Following the Redemption Deadline

Upon consummation of the business combination, the ENVI ticker will transition to “GRNA” and is expected to start trading on the Nasdaq on February 3, 2022

BOSTON, January 28, 2022—Environmental Impact Acquisition Corporation (“ENVI” or the “Company”) (Nasdaq: ENVI) today announced that it had achieved a quorum for the special meeting of its shareholders to be held on February 1, 2022 (the “Special Meeting”), in connection with its business combination with GreenLight Biosciences Inc. (“GreenLight”), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture.

ENVI’s shareholders who have submitted proxies to date on the proposals included in the Company’s proxy statement/prospectus for the Special Meeting have overwhelmingly voted in support of the business combination and all other proposals to be voted on at the meeting. Accordingly, it is anticipated that the business combination and the other proposals will be approved at the Special Meeting. However, shareholders may change or revoke their proxies before or at the Special Meeting.

The business combination, if approved by ENVI shareholders, is expected to close on February 2, 2022. Upon the closing of the business combination, common stock and warrants of the combined company are expected to begin trading on February 3, 2022, on Nasdaq under the ticker symbol GRNA.

Environmental Impact Acquisition Corp. Stockholder Vote

Stockholders who own shares of Environmental Impact Acquisition Corp., as of the Record Date should submit their vote promptly and no later than 11:59 p.m. Eastern Time on January 31, 2022. Environmental Impact Acquisition Corp. stockholders who need assistance in completing the proxy card, need additional copies of the proxy materials, or have questions regarding the Special Meeting may contact Environmental Impact Acquisition Corp.’s proxy solicitor, D.F. King & Co., Inc., by telephone toll-free at (866) 620-2535 or collect at (212) 269-5550 or by email at [email protected]

About GreenLight

Founded in 2008, GreenLight aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective production of RNA. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. For more information, visit https://www.greenlightbiosciences.com/

In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI).

For more information, visit greenlightbiosciences.com

About Environmental Impact Acquisition Corporation

Environmental Impact Acquisition Corp. is a Special Purpose Acquisition Company. The Company is sponsored by CG Investments Inc. VI, an affiliate of Canaccord Genuity, which manages several investment vehicles.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws with respect to the business of GreenLight Biosciences, Inc. and its proposed transaction with Environmental Impact Acquisition Corp. (“ENVI”), including statements regarding the anticipated benefits and uses of GreenLight’s product candidates, the market opportunities for GreenLight’s product candidates, timing of clinical trials, and the timing of commercial launch of product candidates, and the anticipated business combination with ENVI. These forward-looking statements are generally identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from these forward-looking statements, including but not limited to: the need to obtain regulatory approval for GreenLight’s product candidates; the risk that clinical trials will not demonstrate that GreenLight’s therapeutic product candidates are safe and effective; the risk that GreenLight’s product candidates will have adverse side effects or other unintended

consequences, which could impair their marketability; the risk that GreenLight’s product candidates do not satisfy other legal and regulatory requirements for marketability in one or more jurisdictions; the risks of enhanced regulatory scrutiny of mRNA solutions; the risk of significant delays in research, development, testing, clinical trials and regulatory approval; the potential inability to achieve GreenLight’s goals regarding scalability and affordability of its product candidates; the anticipated need for additional capital to achieve GreenLight’s business goals; changes in the industries in which GreenLight operates; changes in laws and regulations affecting the business of GreenLight; the risk that the proposed business combination with ENVI may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities; the failure to satisfy conditions to the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; risks that the proposed transaction disrupts current plans and operations of GreenLight; and the potential inability to implement or achieve business plans, forecasts, and other expectations after the completion of the proposed transaction. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the registration statement on Form S-4 discussed below and other documents filed by ENVI from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Neither ENVI nor GreenLight gives any assurance that GreenLight or ENVI, or the combined company, will achieve any result described in any forward-looking statement.

Important Information and Where to Find It

ENVI has filed a registration statement on Form S-4 with the SEC, which includes a document that serves as a preliminary proxy statement/prospectus of ENVI, referred to as a proxy statement/prospectus. The registration statement was declared effective by the SEC on January 13, 2022 and the definitive proxy statement/prospectus and other relevant documents have been filed with the SEC and mailed to ENVI’s stockholders as of the Record Date.

This press release does not contain all of the information contained in the final proxy statement/prospectus or other documents filed with the SEC. Before making any voting decision, investors and security holders of ENVI are urged to read the registration statement,

the final proxy statement/ prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction. Investors and security holders will be able to obtain free copies of the registration statement, the final proxy statement/prospectus and all other relevant documents filed with the SEC by ENVI through the website maintained by the SEC at www.sec.gov or by sending a written request to ENVI at: [email protected].

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Participants in the Solicitation

ENVI, GreenLight and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from ENVI’s shareholders in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination are contained in the final proxy statement/prospectus. You may obtain free copies of these documents as described above.

Contact:

Thomas Crampton

SVP and Head of Corporate Affairs

GreenLight Biosciences, Inc.

200 Boston Avenue, Suite 1000, Medford, MA 02155

US Mobile: +1 914 202 2762

UK Mobile: +44 7826 995794

Get the link to the full presentation from our teach-in on January 2022 here.

Boston, January 14, 2022/ — Environmental Impact Acquisition Corporation (NASDAQ: ENVI) (“ENVI”), a publicly-traded special purpose acquisition company, announced today that ENVI’s definitive proxy statement/prospectus (the “Proxy Statement”) relating to the previously announced business combination with GreenLight Biosciences, Inc. (“GreenLight”), a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, has been filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 13, 2022.

ENVI has commenced mailing of the Proxy Statement and a notice and voting instruction form or a proxy card relating to the special meeting of ENVI stockholders (the “Special Meeting”) to ENVI stockholders of record as of the close of business on December 29, 2021 (the “Record Date”), who will be entitled to attend and participate in the Special Meeting.

The Special Meeting to approve the proposed business combination and related matters is scheduled to be held on February 1st, 2022 at 9:00 A.M. Eastern time. The Special Meeting will be conducted completely virtually, and can be accessed via live webcast at www.virtualshareholdermeeting.com/ENVI2022SM. If the proposals at the Special Meeting are approved, the parties anticipate that the business combination will close and the trading of the combined entity will commence on NASDAQ shortly thereafter, subject to the satisfaction or waiver, as applicable, of all other closing conditions.

The ENVI Board of Directors believes the proposed business combination is in the best interests of ENVI and its stockholders, and recommends that ENVI stockholders vote “FOR” the adoption and approval of the Business Combination Agreement, dated as of August 10, 2021 (as amended by the First Amendment to the Business Combination Agreement, dated July 27, 2021), by and among ENVI, GreenLight, as well as all other proposals included in ENVI’s Proxy Statement.

Every stockholder’s vote is important, regardless of the number of shares held. Accordingly, ENVI requests that each stockholder complete, sign, date and return a proxy card (online or by mail) as soon as possible so that their votes arrive no later than 11:59 P.M. on January 31, 2022, to ensure that the stockholder’s shares will be represented at the Special Meeting. Stockholders that hold shares in “street name” (i.e., those stockholders whose shares are held of record by a broker, bank or other nominee) should contact their broker, bank or nominee to provide instructions on how to vote their shares and ensure that their shares are voted.

If any individual ENVI stockholder does not receive the Proxy Statement, such stockholder should (i) confirm their Proxy Statement’s status with their broker or (ii) contact D.F. King, ENVI’s proxy solicitor, for assistance via e-mail at [email protected] or toll-free call at (866) 620-2535. Banks and brokers can place a collect call to (212) 269-5550.

ENVI expects to provide stockholders with additional information on how stockholders may vote their shares on its website in the coming days.

About GreenLight

Founded in 2008, GreenLight aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA  to protect honeybees and a range of crops. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective production of RNA. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. For more information, visit https://www.greenlightbiosciences.com/

In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI).

For more information, visit greenlightbiosciences.com

About Environmental Impact Acquisition Corporation

Environmental Impact Acquisition Corp. is a Special Purpose Acquisition Company. The Company is sponsored by CG Investments Inc. VI, an affiliate of Canaccord Genuity, which manages several investment vehicles.

Important Information and Where to Find It

ENVI has filed a registration statement on Form S-4 with the SEC, which includes a document that serves as a preliminary prospectus and proxy statement of ENVI, referred to as a proxy statement/prospectus. The registration statement was declared effective by the SEC on January 13, 2022 and the definitive proxy statement/prospectus and other relevant documents have been filed with the SEC and mailed to ENVI’s stockholders as of the Record Date.

This press release does not contain all of the information contained in the final proxy statement/prospectus or other documents filed with the SEC. Before making any voting decision, investors and security holders of ENVI are urged to read the registration statement, the final proxy statement/ prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.  Investors and security holders will be able to obtain free copies of the registration statement, the final proxy statement/prospectus and all other relevant documents filed with the SEC by ENVI through the website maintained by the SEC at www.sec.gov or by sending a written request to ENVI at: [email protected].

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Participants in the Solicitation

ENVI, GreenLight and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from ENVI’s shareholders in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination are contained in the final proxy statement/prospectus. You may obtain free copies of these documents as described above.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquisition Corp. (“ENVI”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities and the effect of the announcement or pendency of the transaction on GreenLight’s business relationships, operating results, and business generally. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Thomas Crampton

SVP & Head of Corporate Affairs

GreenLight Biosciences

[email protected]

+44 7826 995794

+1-914-202-2762

Environmental Impact Acquisition Corp.

Daniel Coyne

Chief Executive Officer

[email protected]

GreenLight Biosciences, a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, today announced the expansion of its research and development operations in Research Triangle Park (RTP), North Carolina.

The new greenhouse, laboratory, and offices will add more than 60,000 square feet of space and enable the continuing growth of GreenLight’s plant health pipeline, adding more jobs in the process. 

“This additional capacity is a critical step in helping us capitalize on our solutions for agriculture to realize a food-secure future,” says Mark Singleton, head of plant health at RTP. “The investment will help to keep us at the cutting edge of innovation and continue first-of-a-kind progress like we are currently seeing in our fungal program.”

“We expect to have 60 employees on site by the end of 2022, with our new spaces housing various entomology, fungal, and herbicide projects as well as the functions that support them.”

“GreenLight embodies the type of company we envisioned for our Alexandria Center® for AgTech campus, a fully integrated, amenity-rich R&D and greenhouse campus,” said Blake Stevens, vice president of Science & Technology, Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. 

“With the transformative potential of GreenLight’s RNA platform, we have both invested in and provided the company with mission-critical real estate, and we are thrilled to support their rapid growth and efforts to meaningfully improve human health and nutrition in the second phase of our first-of-its-kind agtech campus.”

Occupancy of the new greenhouse, where GreenLight will plant a variety of crops, will begin in the first quarter and increase growing capacity tenfold. Operations will support product research and development as the company works to bring innovative new tools to farmers to address pests and diseases, including botrytis and powdery mildew. 

In 2022, GreenLight expects regulatory approval of its RNA-based product for controlling the Colorado potato beetle and to submit its honeybee health solution to the Environmental Protection Agency. 

The company has seven agricultural products in development with an addressable market of $6 billion that it plans to launch by 2026. In October, GreenLight announced that effective control of fungal pathogens using double-stranded RNA had been achieved for the first time ever. 

About GreenLight

Founded in 2008, GreenLight aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA  to protect honeybees and a range of crops. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective production of RNA. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. For more information, visit https://www.greenlightbiosciences.com/

In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI).

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquisition Corp. (“ENVI”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities and the effect of the announcement or pendency of the transaction on GreenLight’s business relationships, operating results, and business generally. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: 

Thomas Crampton

SVP & Head of Corporate Affairs

GreenLight Biosciences

[email protected]

+44 7826 995794

+1-914-202-2762

“The highly mutated Omicron variant may be partially capable of eluding existing vaccines, so rapid adaptation is an urgent priority,”

The partnership will help advance GreenLight’s messenger RNA COVID-19 vaccine candidate, in support of ongoing global health needs.

 GreenLight Biosciences (Nasdaq: ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services, announced a partnership agreement in which Samsung Biologics will manufacture GreenLight’s messenger RNA COVID-19 vaccine candidate at commercial scale.

The partnership aims to accelerate production of GreenLight’s COVID-19 vaccine candidate for Phase III clinical trials and, subject to regulatory approval, commercial sales. The collaboration with Samsung will leverage GreenLight’s existing manufacturing process, with technology transfer from GreenLight to Samsung starting immediately.

Both Samsung Biologics and GreenLight are committed to vaccine equity and envision a world capable of producing enough messenger RNA vaccine doses for billions of people a year. This supports GreenLight’s ambition to help vaccinate the world against COVID-19, as detailed in its Blueprint To Vaccinate The World published in March 2021. This vision aligns with calls by CEPI, and others for concrete actions to increase vaccine manufacturing capacity across the world, not just for COVID-19, but also for other infectious diseases reflecting the ongoing global health needs.

“We are delighted to partner with Samsung to manufacture messenger RNA for our Covid vaccine trial. There is an urgent need to develop vaccines for the whole world,” said GreenLight CEO Andrey Zarur. “Our vaccine trial will open the way to make vaccines that are available to everybody, not just citizens of developed countries.”

“We are delighted to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA COVID-19 vaccine candidate to better serve patients in lower income countries,” said John Rim, CEO of Samsung Biologics. “This collaboration demonstrates a major milestone for Samsung Biologics as we will commence our expanded capabilities and operations to provide one-stop end-to-end messenger RNA production from Drug Substance (DS) to Aseptic Fill Finish (DP) to commercial release, all from a single site. At this time of urgent global demand, we will strive for seamless service across our biomanufacturing network to fight the COVID pandemic and in turn, help make progress towards Korea’s vaccine hub goal.”

Samsung Biologics has been proactive in accommodating client needs in the biopharma CDMO landscape, including its plans to add messenger RNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022.

About GreenLight

Founded in 2008, GreenLight aims to solve some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. In human health, this includes messenger RNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s breakthrough cell-free dsRNA manufacturing platform, which is protected by numerous patents, allows for cost-effective and scalable production of RNA. For more information, visit https://www.greenlightbiosciences.com.

In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq:ENVI).

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. For more information, visit www.samsungbiologics.com .

GreenLight’s Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquisition Corp. (“ENVI”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities and the effect of the announcement or pendency of the transaction on GreenLight’s business relationships, operating results, and business generally. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Samsung Biologics Forward-Looking Statements

This press release contains certain statements that constitute forward-looking statements, including statements that describe Samsung Biologics’ objectives, plans or goals. All such forward-looking statements, and the assumptions on which they are based, are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. There can be no assurance that the results and events contemplated by the forward-looking statements contained herein will in fact occur. Except as required by law, Samsung Biologics will not update any forward-looking statements to reflect material developments that may occur after the date of this press release.

GreenLight Contact

Thomas Crampton
SVP & Head of Corporate Affairs
GreenLight Biosciences
[email protected] 
+44 7826 995794
+1 914 202 2762

Samsung Biologics Contact
Claire Kim
Senior Director, Global Public Relations
Samsung Biologics
[email protected]

SOURCE Samsung Biologics